Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin for piriformis muscle syndrome (phase IIb)
2024-517948-66-00Phase 2Authorised
- Sponsor
- CHU Nîmes
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Piriformis syndrome comparing Xeomin with Placebo (2 arms). Primary endpoint: Change in sciatic pain intensity at 6 weeks. Planned start Aug 2025; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
Piriformis syndrome
Beyond the preview
Go deeper on 2024-517948-66-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517948-66-00.